Evidence map›Paper›PMID 23626900›Full record

ArticleChemical science2013

Kinetics and Mechanisms of Oxidative Cleavage of HIV RRE RNA by Rev-Coupled Transition Metal Chelates.

Jeff C Joyner, Kevin D Keuper, J A Cowan

Abstract read
In one paragraph

Article in Chemical science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Catalytic metallodrugs based on the LaR2C peptide target HCV SLIV IRES RNA.Dalton transactions (Cambridge, England : 2003) · 2015
    Article
  8. Review
  9. Article
  10. Target-directed catalytic metallodrugs.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jeff C JoynerEvans Laboratory of Chemistry, Ohio State University, 100 West 18th Avenue, Columbus, Ohio 43210 ; The Ohio State Biochemistry Program, 784 Biological Sciences 484 W. 12th Avenue, Columbus, Ohio 43210.
Kevin D Keuper
J A Cowan

Funding

CHEMISTRY/BIOLOGY TRAINING GRANTT32GM008512 · NIGMS · OHIO STATE UNIVERSITY · PI PEI, DEHUA · 1996 to 2016
$3.9M
Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV InfectionR44AA016712 · NIAAA · METALLOPHARM, LLC · PI COWAN, ADA S · 2011 to 2013
$2.0M
METALLOPEPTIDES AS THERAPEUTIC AGENTSR21HL093446 · NHLBI · OHIO STATE UNIVERSITY · PI COWAN, JAMES A · 2009 to 2010
$408k
Novel Engineered Synthetic Metallodrugs Directed Against HCVR43AA016712 · NIAAA · METALLOPHARM, LLC · PI CHING, SAN · 2007 to 2008
$257k
NHLBI NIH HHS R21 HL093446NIAAA NIH HHS R43 AA016712NIAAA NIH HHS R44 AA016712NIGMS NIH HHS T32 GM008512
6 · The paper itself

Abstract

Catalytic metallodrugs were used to oxidatively cleave HIV-1 Rev Response Element RNA (RRE RNA), and the mechanisms of RNA cleavage were studied using a combination of matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), fluorescence spectroscopy, and gel electrophoresis. The metallodrugs, which contained combinations of the transition metals Fe

Indexed as

2-hydroxypropanedialartificial nucleasesbase 2-hydroxypropenalcatalytic metallodrugscleavagedamageendonucleolysisHIVhydrogen abstractionhydrolysisMALDI-TOFmass spectrometrymechanismsoxidationRNARREscissiontartronalthiobarbituric acid

Identifiers

PMID23626900
PMCPMC3634708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.